# Administrative Core

> **NIH NIH P20** · UNIVERSITY OF LOUISVILLE · 2024 · $1,025,924

## Abstract

The University of Louisville Hepatobiology and Toxicology COBRE is a multidisciplinary group of 
investigators focusing on the liver and liver injury, gut:liver interactions, and liver:environment/toxicant/drug 
interactions, alcoholic and non-alcoholic liver injury, infectious liver diseases, liver cancer, and new liver 
therapies. The purpose of the administrative core is to provide administrative, fiscal and scientific oversight for 
this Phase II COBRE. This includes the overall career development and research goals of the Phase II 
COBRE (including formative and summative evaluation and specific milestones); the career development plans 
for junior faculty (including plans for transitioning to independence); plans for replacing key personnel (e.g., 
Project PIs, Core leaders, overall PI, pilot project PIs); oversight of the pilot projects; oversight of the 
biostatistical support services; and disseminating information to the lay and scientific communities. 
 Liver diseases are some of the most common, rapidly increasing and poorly recognized health 
problems afflicting Americans. For example, Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis 
is the most common cause of abnormal liver enzymes in the US, affecting about 25% of adults and about 10% 
of children. Alcoholic Liver Disease is an increasing problem among those who drink. Importantly, there is no 
FDA-approved therapy for either NASH or ALD. Toxicant-Induced Liver Injury is an increasingly recognized 
industrial/environmental problem. Viral Liver Diseases (Hepatitis A, B, and C) remain major health problems 
related to drug abuse and homelessness. Hepatocellular carcinoma and Hepatitis C are major causes for liver 
related morbidity and liver transplantation in the US. Drug-Induced Liver Injury is the major reason new drugs 
do not come to market and the major cause of fulminant liver failure in the US. Personalized Medicine is 
increasingly recognized as an important aspect of drug therapy; and most drugs are metabolized in the liver. 
 Building on the success of the Phase I COBRE Administrative Core, the specific aims of this Phase II 
COBRE Administrative Core are: 
 1. continue to provide overall administrative, fiscal and scientific oversight 
 2. enhance and grow the career development enterprise for project PIs 
 3. enhance and grow the career development/mentor development enterprise for the mentors 
 4. enhance and grow the research goals of the COBRE 
 5. continue to provide a process for replacing key personnel 
 6. continue to provide and enhance a summative and formative evaluation process for the COBRE, 
 including specific milestones 
 7. continue to provide a robust pilot project program to grow the overall research goals of the COBRE 
 8. disseminate pertinent information to the scientific and lay community

## Key facts

- **NIH application ID:** 10844402
- **Project number:** 5P20GM113226-09
- **Recipient organization:** UNIVERSITY OF LOUISVILLE
- **Principal Investigator:** CRAIG J. MCCLAIN
- **Activity code:** P20 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,025,924
- **Award type:** 5
- **Project period:** 2016-06-10 → 2026-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10844402

## Citation

> US National Institutes of Health, RePORTER application 10844402, Administrative Core (5P20GM113226-09). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10844402. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*